Lymphoma Clinical Trial
Official title:
Acupuncture for Chemo-induced Peripheral Neuropathy in Multiple Myeloma and Lymphoma Patients
The goal of this clinical research study is to learn if giving acupuncture to patients with lymphoma or a plasma cell dyscrasia can help to relieve numbness and/or tingling of the feet and/or hands that is related to chemotherapy.
Acupuncture:
Acupuncture involves the insertion of small, solid, sterile needles into specific points on
the skin. In this study, the needles are placed in areas that are intended to help relieve
numbness and tingling of the feet and hands. Weak electrical stimulation is also applied to
the needles to try to improve the treatment effects of the acupuncture.
Acupuncture Sessions:
Your first acupuncture session will be on the same day as the tests described above, if
possible. (If not, it will be scheduled for another day that will be no more than about 10
days after the screening visit.)
You will have an acupuncture session 3 times per week for 4 weeks (Weeks 1-4). You will then
have 1 week off (Week 5). After that, you will have an acupuncture session twice per week
for 4 more weeks (Weeks 6-10). This is a total of 20 sessions. In addition to the 20 planned
sessions, you may also choose to receive an optional 21st acupuncture session at the
end-of-study visit that is scheduled for Week 13.
For each session, you will be placed in a comfortable position and the study
doctor/acupuncturist will find points on your body where the needles will be placed. All
study participants will have the needles placed at the same points on the body (the hands,
feet, legs, abdomen, and scalp).
Very thin, solid, sterile, stainless steel needles will be used. All of the needles are
specially made for acupuncture. The depth of the needle in the skin and the number of
needles used is based on standard acupuncture procedures. The needles will remain in place
for about 20-30 minutes.
Electrical stimulation will be added to some of the needles on the feet and hands. This
involves placing wires on the needles, which are connected to a machine that delivers a weak
electrical current through the wires. The strength of the electrical current will be changed
slowly until it is at a comfortable level for you.
Study Procedures:
At each session, before you receive the acupuncture, the following procedures will be
performed:
- Your vital signs will be measured.
- You will be asked about any drugs you may be taking and any side effects you may be
experiencing.
- The color and coating of your tongue and the quality of your pulse will be recorded.
Once a week, you will also be asked to complete the same 3 questionnaires as you did at the
beginning of the study.
Most study visits will last about 1 hour. On the weeks that you complete the questionnaires,
it may add about 15-20 minutes.
During the study, you may still receive your regular pain treatments. If you are receiving
Neurontin (gabapentin), Cymbalta (duloxetine), and/or Lyrica (pregabalin), you must stay on
the same drug(s) until you go off this study. Minor changes in the doses of your pain
treatments are allowed, but if there is a large change, you will be taken off study early.
Length of Study Participation:
You may receive up to 21 acupuncture sessions over 13 weeks. If intolerable side effects or
symptoms occur, you will be taken off study early.
End-of-Study Visit:
At Week 13, or if you go off study early for any reason, you will have an end-of-study
visit. If the doctor thinks it is necessary, the following procedures will be performed:
- Your medical history will be recorded.
- Your vital signs will be measured.
- You will be asked about any drugs you may be taking and any side effects you may have
experienced.
- You will complete the same 3 questionnaires as before.
- The 4 nerve tests will be repeated in order to learn if there have been any changes in
your nerve function.
- Your tongue and pulse will be evaluated.
After the end-of-study visit, your participation in this study will be over.
This is an investigational study. The acupuncture needles used in this study are
commercially available and FDA approved. It is considered experimental, however, to use
acupuncture to treat numbness and/or tingling in the feet and/or hands that is related to
chemotherapy.
Up to 30 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |